Soared 50% Again!

Red Star Capital Bureau, September 16 — Today at market open, TransThera Sciences-B (02617.HK) surged again, with an intraday increase of over 63%, reaching HK$679.5 per share. As of press time, TransThera Sciences was up 51.57% at HK$629 per share, with a latest market capitalization of HK$249.65 billion and a turnover rate of only 1.06%.

Founded in 2014 and headquartered in Nanjing, Jiangsu, TransThera Sciences is an innovative pharmaceutical company focused on small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases. It listed on the main board of the Hong Kong Stock Exchange on June 23 this year. On September 8, TransThera Sciences was included in the Hong Kong Stock Connect list. After its inclusion, mainland investors can directly participate in trading the stock through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs.

The surge in TransThera Sciences' stock price is closely related to high market expectations for its core product, Tinengotinib (TT-00420). On September 10, TransThera Sciences announced that its Phase II clinical trial of Tinengotinib combined with fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative or low-expression (HER2-) recurrent or metastatic breast cancer in patients who have failed prior therapies received implicit clinical approval from China's National Medical Products Administration (NMPA) on the same day.

It is important to note that Tinengotinib is currently in Phase II clinical trials, and TransThera Sciences has no other commercialized products on the market, with continued financial losses. The company has not been profitable in its 11 years of operation. In the first half of 2025, the company still reported no revenue, with R&D expenses of RMB 98.43 million and administrative expenses of RMB 27.47 million, resulting in a net loss of RMB 123 million during the period. Additionally, drug development is fraught with uncertainties, and it remains difficult to predict whether Tinengotinib will be successfully launched or how it will perform commercially post-launch.